The company is developing a viral-free genome surgery platform that allows for the precise insertion of any genetic sequence into disease-relevant human cells. This technology aims to enable medical professionals to effectively treat severe genetic disorders and cancer by providing a reliable method for genomic modification.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene therapy methods often rely on viral vectors for gene delivery, which can trigger immune responses, have limited cargo capacity, and pose risks of off-target effects. Existing non-viral methods lack the efficiency and precision needed for effective in vivo genome editing, particularly for complex genetic diseases and cancers.
Solution
The company is developing a non-viral genome surgery platform for precise and efficient insertion of genetic sequences into human cells. This technology aims to overcome the limitations of viral vectors by offering a safer and more controllable method for genomic modification. The platform is designed to enable targeted delivery of therapeutic genes or gene-editing tools directly to disease-relevant cells, minimizing off-target effects and maximizing therapeutic efficacy. By providing a reliable and precise method for genomic modification, the company seeks to advance the treatment of severe genetic disorders and cancer.
Target Audience
The primary target audience includes medical professionals and researchers focused on gene therapy, particularly those working on treatments for severe genetic disorders and cancer.
Features
- Non-viral delivery system for enhanced safety and reduced immunogenicity
- Precise insertion of genetic sequences at targeted genomic locations
- High cargo capacity for delivery of large or multiple genes
- Customizable platform for various cell types and disease applications